Biggest News Aggregation in the World
๐Ÿ“ฐ Liso Cel News

Page 2 - Liso Cel News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Liso Cel. Real-time updates on events, politics, business and more.

Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL

Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.
Mazyar Shadman National Comprehensive Cancer Network Clinical Research Division Oncology Division Hematologic Malignancies At Fred Hutchinson Cancer Center University Of Washington School Medicine

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Anne Kerber Cell Therapy Development At Bristol Myers Squibb European Commission Cell Therapy Development Bristol Myers Squibb Cart Cell Therapy

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Liso-cel Receives European Approval Recommendation for Relapsed/Refractory LBCL

The European Medicines Agencyโ€™s Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of select patients with large B-cell lymphoma who relapsed within 12 months from completion of or developed refractory disease to frontline chemoimmunotherapy.
Bristol Myers Squibb Anne Kerber European Union European Commission European Medicines Agency Cell Therapy Development

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science